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H EMOLYTIC uremic syndrome (HUS) is known to be 
a leading cause of acute renal failure in children. 
When seen in ;dults. it may often be sporadic. or familial. 1 
The results of renal transplantation with cyclosporine 
(CyA) in patients with HUS as the cause of end-stage renal 
disease (ESRD) have been reported in many series.2- 4 We 
previously reported our experience with renal transplanta-
tion for HUS under FK506 (Prograf) immunosuppression.5 
In this article. we describe our overall results of kidney 
transplantation for renal failure due to HUS treated with 
either CyA or FK 506 (Prograf) as the main immunosup-
pressive agent. 
PATIENTS AND METHODS 
All patients who undetwent renal transplantation with a diagnosis 
of HUS as the cause of renal failure were studied. Seven adults and 
four children received a total of 16 kidneys. One child received two 
cadaveric kidneys; the first graft was treated with CyA and the 
second with FK 506. A second patient received five cadaveric 
transplants. CyA was used for the third and fourth transplants. 
while the fifth was performed with FK 506 (the first two transplants 
were with azathioprine and prednisone). The fourth kidney was 
transplanted elsewhere and lost to a technical error at I week. This 
graft. plus the first two transplanted kidneys were excluded from 
analysis. 
All other patients received a single kidney; three were from living 
donors. and six were from cadaveric donors. Five cases received 
CyA as the main immunosuppressive agent, with FK 506 as the 
primary agent in eight cases. The immunosuppressive regimen 
consisted of CyA or FK 506 and prednisone. with or without 
azathioprine (AZA). Two patients received OKT3 for induction 
therapy at the time of retransplantation with FK 506. 
The clinical features are described in Table 1. A diagnosis of 
recurrent HUS was made if the following features were present: 
progressive thrombocytopenia; and hemolytic anemia and a rising 
serum creatinine without evidence of rejection by histological 
examination of a kidney biopsy. 
RESULTS 
Children 
Four children received a total of five cadaveric kidneys. All 
were treated with FK 506; in addition. one child received a 
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Table 1 
Patient Age at Ox HUS Age at Tx Type of Tx Family Hx Onset of Disease Drug Therapy Outcome 
3.5mo 11 mo CAD yes 5d CyA dialysis 
3.5 mo 4.5 y CAD yes 5d FK 506 dialYSIS 
2 7y 8.5 Y CAD no FK 506 GF at 3.5 y 
3 16mo 3y CAD no FK 506 GF at 3.3 y 
4 23mo 10 y CAD no FK506 GF at 4.3 y 
5 22 mo 18 y LAD no FK506 GF at 2.8 y 
6 28 Y 28.8 Y CAD no CyA GF at 8.7 y 
7 22mo 29y LAD no CyA Graft loss to pyelonephritis 
and CR at 4.9 y 
8 25 Y 26y LUD no 19 days CyA Graft loss at 4.5 mo, died 
at 1.2 y 
9 38y 42 Y CAD no FK 506 GF at 2.9 y 
10 37 Y 41 Y CAD ves 4wk FK506 Graft loss at 1 mo died 
at 1.7 Y 
11 13.5 Y 14 Y CAD x 5 no Imuran Graft loss at 10 Y (CA) 
25 V Imuran Graft loss at 3 wk (PNF) 
25 y CyA Graft loss at 2 V (CA) 
29y CyA Graft loss at 1 wk (Tech) 
32 y FK 506 GF at 4 y 
LAD ~ liVing related donor. LUD = liVIng unrelated dOnor. CAD = cadavenc donor, GF = gOOd functIon. PNF = Primary nonfunctoon, Tech = tecMlcal. 
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CvA AND FK 506 FOR HUS 
first graft under CyA immunosuppression. Both kidne\, 
transplants in this child (performed at ages II months and 
4.5 years) failed due to recurrent HUS documented hy day 
5 posttransplantation. Allograft nephrectomies led to reso-
lution of the hematologic abnormalities. No rejection was 
reported at the time of recurrence of the disease. This child 
had a maternal aunt who died of HUS at I year of age. 
The remaining three patients (75%) are well 3.3 to 4.3 
years posttransplantation without any evidence of recurrent 
HUS and with good graft function (Table I). 
Adults 
Seven adults received a total of eight kidneys for analysis. 
Patient number 11 was transplanted initially at age 14 years. 
and at age 32 she received her fifth kidney transplant (grafts 
1, 2. and 4 were excluded from analysis). All kidneys were 
cadaveric in nature. The remaining 6 adults each underwent 
a single kidney transplant (Table 1). 
Two adults developed recurrent HUS documented bv 
renal biopsy. One recipient gave a family history of HUS i~ 
two first cousins and developed recurrent HUS by 4 weeks 
posttransplantation under FK 506 therapy. Having returned 
to dialysis. she died from secondary septicemia and throm-
botic thrombocytopenia purpura (TTP) 1.7 years posttrans-
plantation. A second adult died; recurrence of HUS was 
seen by day 19 posttransplantation under CyA immunosup-
pression. After multiple unrelated complications, this 
patient died at 14 months posttransplantation. and 9.5 
months after allograft nephrectomy. 
The remaining five adults (71 %) remain free of recurrent 
disease. Two patients were treated with CyA and three 
received FK 506 immunosuppression (one patient received 
CyA with a previous graft). One CyA-treated patient lost 
her graft after 4.9 years due to severe pyelonephritis and 
chronic rejection. Patient number 11 developed no recur-
rence of HUS with either CyA or FK 506 therapy. 
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DISCUSSION 
The recurrence of hemolytic uremic syndrome after kidney 
transplantation with cyclosporine. and more recent Iv with 
FK 506. has been reponed. When we compare the outcome 
of II patients treated with either CyA or FK 506. we tind 
that two of five grafts were lost to recurrent HUS under 
CyA therapy (40C;:c). and two of eight grafts were lost with 
FK 506 immunosuppression (25%). Although our numbers 
are small. the recurrence of this disease seems to correlate 
more with a positive family history for HUS than with the 
type of immunosuppression used. One patient. without a 
family history of HUS. developed recurrent disease at 
3 weeks posttransplantation. Having received a kidney from 
an unrelated donor. the onset of early rejection after 
transplantation could have been a contributing factor in her 
disease onset. However. no rejection was documented at 
the time of recurrent HUS. 
Although our experience suggests that HUS can reoccur 
with either CyA or FK 506 immunosuppressive therapy. the 
incidence is seemingly (but not statistically) lower with FK 
506. The familial form of HUS appears to have a poorer 
outcome (two of two patients) than the spontaneously 
acquired form (one of nine patients). The overall I-year 
graft survival for this patient population remains at 700(. 
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